Please login to the form below

Not currently logged in

EU approves new use of Roche's RoActemra in children

Swiss pharma firm hopes to increase revenue from arthritis drug to tip it into blockbuster status

Roche Basel Switzerland

The European Medicines Agency (EMA) has approved Roche's autoimmune drug RoActemra for a rare form of arthritis in children.

Specifically, the EU medicines regulator has given RoActemra (tocilizumab) the green light to treat children with polyarticular juvenile idiopathic arthritis (PJIA) – a rare, chronic and debilitating form of childhood arthritis.

The medicine can be used to treat patients two years of age and older who have not responded adequately to treatment with methotrexate (MTX), a disease-modifying anti-rheumatic drug.

RoActemra, also known as Actemra outside of Europe, is already approved for moderate to severe active rheumatoid arthritis in adults, and systemic juvenile idiopathic arthritis in children.

The drug brought in 842m Swiss francs ($900m) last year for these indications and Roche will hope that by extending its licence, this will increase RoAcemtra's overall revenue, and bring it to blockbuster status.

These hopes will be boosted by an earlier than expected approval in PJIA, with the EMA's decision coming just one month after a positive Committee for Medicinal Products for Human Use (CHMP) opinion. It usually takes three months for a drug to receive final approval by the Agency after the CHMP has made a recommendation.

Hal Barron, Roche's chief medical officer, welcomed the EMA's swiftness, adding: “We can now quickly provide these young patients with this medicine that we hope will help them to better manage their disease symptoms and allow them to pursue an active lifestyle.”

Despite being rare, this is not the first drug to receive marketing approval for this disease, with Bristol-Myers Squibb's Orencia also holding a European licence to treat PJIA.

PJIA is a form of juvenile idiopathic arthritis, also known as juvenile rheumatoid arthritis, and affects around 100 in every 100,000 children, with PJIA accounting for around 30 per cent of cases.

The condition is characterised by inflammation in five or more joints within the first six months of the disease and most commonly affects the small joints in the body, such as those in the hands and feet.

10th June 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...